Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery

NCT: NCT06204159 · ACTIVE_NOT_RECRUITING

NCT IDNCT06204159
StatusACTIVE_NOT_RECRUITING
Start Date2024-02-01
Completion2026-12-31
SponsorAbramson Cancer Center at Penn Medicine (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with delivery in the type of catheter used during the TACE procedure? Participants will be asked to undergo a TACE procedure, a CT scan and review of their medical record to compare End Hole and TriNav catheters during TACE procedures.

Frequently Asked Questions

What is Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery?

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery is a clinical trial registered under NCT06204159. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06204159?

The current status of NCT06204159 (Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery) is: ACTIVE_NOT_RECRUITING.

When did Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery start?

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery started on 2024-02-01.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.